ArticleBMJ (Clinical research ed.)2022
Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study.
Article in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06695377 (Thromboembolic Complications Post-COVID-19), which is not on this map. Cited by 214 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Thromboembolic Complications Post-COVID-19: What is the Risk in Mild-Moderate Cases?
Who cites it
214 citing papers in PubMed, 8 syntheses or guidelines pooled it, 385 citations in OpenAlex.
- Pharmacologic Thromboprophylaxis in Medical Inpatients: A Systematic Review and Network Meta-Analysis.JAMA network open · 2026Pooled it
- Antithrombotic strategies in adult COVID-19 patients: a systematic review and Bayesian network meta-analysis.BMJ open · 2025Pooled it
- An urgent call to publish COVID-19 trials: a systematic search revealed ZERO studies regarding the incidence of thromboembolic events in SARS-CoV-2 Omicron-infected COVID-19 patients.Critical care (London, England) · 2025Pooled it
- Venous thromboembolism risk in the postoperative interval during the COVID-19 pandemic: meta-analysis.BJS open · 2025Pooled it
- Pooled it
- Are Pre-Hospitalization ECG Abnormalities Associated With Increased Mortality in COVID-19 Patients? A Quantitative Systematic Literature Review.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2024Pooled it
- Estimated causal effects of common respiratory infections on cardiovascular risk: a meta-analysis.Open heart · 2023Pooled it
- Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Efficacy of Atorvastatin Against Venous Thromboembolism After Total Hip Arthroplasty.Journal of musculoskeletal & neuronal interactions · 2025Trial
- Excess cardiovascular risk associated with community-acquired lower respiratory tract infections: a population-based nested self-controlled case-series.BMC medicine · 2026Article
- Trends and Disparities in Mortality due to Pulmonary Embolism Among Adults With Atrial Fibrillation From 1999 to 2020: Insights From the CDCWONDER Database.Journal of arrhythmia · 2026Article
- Venous and arterial thromboembolic events after COVID-19 during the Omicron period in three European countries.Scientific reports · 2026Article
- Antiplatelet activity of a Korean red ginseng-derived saponin fraction and its inhibition of influenza A virus-induced thrombosis.Journal of ginseng research · 2026Article
- Global, regional, and national burden of injury associated internal hemorrhage in the abdomen and pelvis from 1990-2021.Communications medicine · 2026Article
- Antibiotic consumption and prescription patterns in a tertiary care hospital in Karachi, Pakistan: a cross-sectional study.BMC infectious diseases · 2026Article
- Assessment and Incidence Determination of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following a SARS-CoV-2 Infection in a Prospective Cohort of Hospital Employees.Medicina (Kaunas, Lithuania) · 2026Article
- Benign Adrenal Adenomas Are Associated With Reduced Prevalence of Hospitalised Patients With COVID-19.Clinical endocrinology · 2026Article
- Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019.Scientific reports · 2026Article
- MicroRNAs in Long COVID: Key Regulators, Biomarkers, and Therapeutic Targets of Post-SARS-CoV-2 Sequelae.Biomolecules · 2026Review
- Impact of the SARS-CoV-2 pandemic on healthy aging and functionality in older Mexican adults: insights from the MHAS cohort.Aging clinical and experimental research · 2026Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo quantify the risk of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19.
designSelf-controlled case series and matched cohort study.
settingNational registries in Sweden.
participants1 057 174 people who tested positive for SARS-CoV-2 between 1 February 2020 and 25 May 2021 in Sweden, matched on age, sex, and county of residence to 4 076 342 control participants. MAIN OUTCOMES MEASURES: Self-controlled case series and conditional Poisson regression were used to determine the incidence rate ratio and risk ratio with corresponding 95% confidence intervals for a first deep vein thrombosis, pulmonary embolism, or bleeding event. In the self-controlled case series, the incidence rate ratios for first time outcomes after covid-19 were determined using set time intervals and the spline model. The risk ratios for first time and all events were determined during days 1-30 after covid-19 or index date using the matched cohort study, and adjusting for potential confounders (comorbidities, cancer, surgery, long term anticoagulation treatment, previous venous thromboembolism, or previous bleeding event).
resultsCompared with the control period, incidence rate ratios were significantly increased 70 days after covid-19 for deep vein thrombosis, 110 days for pulmonary embolism, and 60 days for bleeding. In particular, incidence rate ratios for a first pulmonary embolism were 36.17 (95% confidence interval 31.55 to 41.47) during the first week after covid-19 and 46.40 (40.61 to 53.02) during the second week. Incidence rate ratios during days 1-30 after covid-19 were 5.90 (5.12 to 6.80) for deep vein thrombosis, 31.59 (27.99 to 35.63) for pulmonary embolism, and 2.48 (2.30 to 2.68) for bleeding. Similarly, the risk ratios during days 1-30 after covid-19 were 4.98 (4.96 to 5.01) for deep vein thrombosis, 33.05 (32.8 to 33.3) for pulmonary embolism, and 1.88 (1.71 to 2.07) for bleeding, after adjusting for the effect of potential confounders. The rate ratios were highest in patients with critical covid-19 and highest during the first pandemic wave in Sweden compared with the second and third waves. In the same period, the absolute risk among patients with covid-19 was 0.039% (401 events) for deep vein thrombosis, 0.17% (1761 events) for pulmonary embolism, and 0.101% (1002 events) for bleeding.
conclusionsThe findings of this study suggest that covid-19 is a risk factor for deep vein thrombosis, pulmonary embolism, and bleeding. These results could impact recommendations on diagnostic and prophylactic strategies against venous thromboembolism after covid-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.